MARKET

OCGN

OCGN

Ocugen Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.19
-0.40
-4.12%
After Hours: 9.06 -0.13 -1.36% 19:59 05/07 EDT
OPEN
8.04
PREV CLOSE
9.58
HIGH
9.86
LOW
7.61
VOLUME
177.79M
TURNOVER
--
52 WEEK HIGH
18.77
52 WEEK LOW
0.1700
MARKET CAP
1.82B
P/E (TTM)
-25.1920
1D
5D
1M
3M
1Y
5Y
DJ Ocugen's CEO Shankar Musunuri on Q1 2021 Results -- Earnings Call Transcript >OCGN
Dow Jones · 1d ago
Cantor Fitzgerald Downgrades Ocugen to Neutral, Lowers Price Target to $11
Cantor Fitzgerald analyst Kristen Kluska downgrades Ocugen (NASDAQ:OCGN) from Overweight to Neutral and lowers the price target from $15 to $11.
Benzinga · 1d ago
Ocugen (OCGN) Miss Earnings & Revenues Estimates in Q1
Zacks · 1d ago
Regional Health Properties, Auris Medical leads healthcare gainers; ChemoCentryx, Orphazyme among major losers
Gainers: Regional Health Properties (RHE) +39%, Auris Medical (EARS) +26%, Clene (CLNN) +25%, Pro-Dex (PDEX) +20%, Epizyme (EPZM) +17%.Losers: ChemoCentryx (CCXI) -59%, Orphazyme (ORPH) -30%, F-star Therapeutics (FSTX) -21%, Aurinia Pharmaceuticals (AUPH) ...
Seekingalpha · 1d ago
Thinking about buying stock in Acasti Pharma, Ocugen, Castor Maritime, Naked Brand, or Auris Medical?
, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACST, OCGN, CTRM, NAKD, and EARS.
PR Newswire - PRF · 1d ago
Ocugen slips after Q1 results shows rising costs amid progress in COVID-19 vaccine front
Ocugen ([[OCGN]] -18.8%) has lost double-digits in percentage terms for the fourth consecutive day after the company’s Q1 2021 earnings came worse than expected as R&D costs and G&A expenses
Seekingalpha · 1d ago
--Cantor Fitzgerald Downgrades Ocugen to Neutral From Overweight, Adjusts PT to $11 From $15
MT Newswires · 2d ago
10-Q: OCUGEN, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OCGN. Analyze the recent business situations of Ocugen Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OCGN stock price target is 9.00 with a high estimate of 13.00 and a low estimate of 1.000.
EPS
Institutional Holdings
Institutions: 65
Institutional Holdings: 20.59M
% Owned: 10.39%
Shares Outstanding: 198.17M
TypeInstitutionsShares
Increased
7
2.55M
New
28
1.34M
Decreased
5
3.15M
Sold Out
3
42.05K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Chief Executive Officer/Director
Shankar Musunuri
Chief Financial Officer/Chief Accounting Officer/Treasurer
Sanjay Subramanian
Senior Vice President
Vijay Tammara
Vice President/Secretary/IR Contact Officer
Kelly Beck
Independent Director
Kirsten Castillo
Independent Director
Prabhavathi Fernandes
Independent Director
Uday Kompella
Independent Director
Ramesh Kumar
Independent Director
Manish Potti
Independent Director
Suha Taspolatoglu
Independent Director
Junge Zhang
No Data
About OCGN
Ocugen, Inc., formerly Histogenics Corporation is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of therapies for eye diseases. The Company offers a diversified ophthalmology portfolio that includes gene therapies, biologics, and small molecules and targets a range of retinal and ocular surface diseases. The Company is leveraging its modifier gene therapy platform to address genetically diverse inherited retinal disorders and dry age-related macular degeneration (AMD), based on nuclear hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The Company is also developing biologic therapies for wet-AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as for retinitis pigmentosa (OCU100).

Webull offers kinds of Ocugen Inc stock information, including NASDAQ:OCGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OCGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OCGN stock methods without spending real money on the virtual paper trading platform.